Boston Scientific Co. (NYSE:BSX) Shares Sold by Conning Inc. – Riverton Roll

Conning Inc. cut its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 3.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 20,039 shares of the medical equipment providers stock after selling 800 shares during the period. Conning Inc.s holdings in Boston Scientific were worth $906,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. Allworth Financial LP grew its stake in Boston Scientific by 22.8% in the fourth quarter. Allworth Financial LP now owns 1,345 shares of the medical equipment providers stock worth $61,000 after purchasing an additional 250 shares in the last quarter. Contravisory Investment Management Inc. grew its stake in Boston Scientific by 17.1% in the fourth quarter. Contravisory Investment Management Inc. now owns 1,796 shares of the medical equipment providers stock worth $81,000 after purchasing an additional 262 shares in the last quarter. Whittier Trust Co. grew its stake in Boston Scientific by 25.2% in the third quarter. Whittier Trust Co. now owns 1,338 shares of the medical equipment providers stock worth $54,000 after purchasing an additional 269 shares in the last quarter. Advisor Partners LLC grew its stake in Boston Scientific by 0.6% in the fourth quarter. Advisor Partners LLC now owns 44,221 shares of the medical equipment providers stock worth $1,882,000 after purchasing an additional 270 shares in the last quarter. Finally, LS Investment Advisors LLC grew its stake in Boston Scientific by 0.7% in the third quarter. LS Investment Advisors LLC now owns 41,926 shares of the medical equipment providers stock worth $1,706,000 after purchasing an additional 275 shares in the last quarter. Institutional investors own 91.21% of the companys stock.

A number of equities analysts recently commented on BSX shares. Needham & Company LLC downgraded Boston Scientific from a strong-buy rating to a buy rating and set a $53.00 price target for the company. in a research note on Thursday, December 19th. Cowen reiterated a buy rating and issued a $52.00 price target on shares of Boston Scientific in a research note on Wednesday, January 15th. Wells Fargo & Co lifted their price target on Boston Scientific from $48.00 to $52.00 and gave the stock an overweight rating in a research note on Monday, December 16th. Raymond James decreased their price target on Boston Scientific from $50.00 to $48.00 and set a strong-buy rating for the company in a research note on Monday, October 14th. Finally, JPMorgan Chase & Co. lifted their price target on Boston Scientific from $50.00 to $55.00 and gave the stock an overweight rating in a research note on Friday, December 20th. One research analyst has rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the companys stock. The stock presently has an average rating of Buy and a consensus price target of $48.62.

Shares of BSX stock opened at $43.41 on Friday. The company has a quick ratio of 0.77, a current ratio of 1.14 and a debt-to-equity ratio of 0.99. The business has a 50 day moving average of $44.66 and a two-hundred day moving average of $42.48. Boston Scientific Co. has a 52 week low of $34.35 and a 52 week high of $46.62. The company has a market cap of $61.26 billion, a P/E ratio of 56.38, a PEG ratio of 2.15 and a beta of 0.78.

In other news, SVP Desiree Ralls-Morrison sold 4,050 shares of Boston Scientific stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $45.50, for a total transaction of $184,275.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Williamson Scott purchased 250,000 shares of the businesss stock in a transaction dated Monday, November 4th. The shares were acquired at an average cost of $0.12 per share, for a total transaction of $30,000.00. Over the last 90 days, insiders sold 213,828 shares of company stock valued at $9,485,639. 0.66% of the stock is currently owned by insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Featured Story: What is included in the gross domestic product?

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Read the original here:
Boston Scientific Co. (NYSE:BSX) Shares Sold by Conning Inc. - Riverton Roll